Risankizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Risankizumab: From Psoriasis to Dermatitis
One-Sentence Summary
Risankizumab (Skyrizi) is an anti-IL-23p19 monoclonal antibody originally approved for moderate-to-severe psoriasis (first approved in Japan in 2019, per literature record). The TxGNN model predicts it may also be effective for Dermatitis — with the strongest signal pointing to atopic dermatitis — supported by 7 clinical trials (including one completed Phase 2 RCT specifically in atopic dermatitis) and 20 publications, though this remains a secondary, less mechanistically typical signal compared to its established psoriasis indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this jurisdiction (drug not marketed locally); per literature (PMID 31098898), first global approval was for psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis |
| Predicted New Indication | Dermatitis (evidence concentrated in atopic dermatitis) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L2 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data was flagged as a data gap in this evidence pack. Based on information recovered from the accompanying literature (PMID 31098898), risankizumab is a humanized IgG monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), blocking downstream Th17-pathway signaling. This mechanism is well established as pathogenic in plaque psoriasis, which is why risankizumab is already an approved biologic for that condition (confirmed by Phase 4 trials NCT05969223 and NCT04908475 in this pack, both of which test risankizumab against its existing psoriasis indication rather than a new one).
The predicted indication “dermatitis” is a broad category, and the clinical/literature evidence in this pack is concentrated almost entirely on atopic dermatitis (AD), a distinct disease driven primarily by the Th2/Th22 axis rather than Th17/IL-23. This is mechanistically less typical than psoriasis, but not implausible — IL-22 and, to a lesser extent, IL-23 have been implicated in AD pathophysiology, providing rationale for testing IL-23 blockade in this population.
The strongest piece of direct evidence is a completed Phase 2, randomized, double-blind, placebo-controlled trial (NCT03706040 / PMID 36588137) that directly evaluated risankizumab in moderate-to-severe AD in adults and adolescents. This is a genuine repurposing signal — a real interventional trial outside the approved psoriasis indication — but it is a single Phase 2 study, and other trials in the evidence pack (e.g., real-world psoriasis cohort studies, pediatric biologics reviews) are only indirectly relevant, since they describe risankizumab’s use in its already-approved psoriasis indication or discuss it alongside other biologics rather than testing it in AD.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03706040 | Phase 2 | Completed | 172 | Randomized, double-blind, placebo-controlled trial assessing safety/efficacy of risankizumab in moderate-to-severe atopic dermatitis in adults and adolescents — the key direct repurposing evidence. |
| NCT05969223 | Phase 4 | Completed | 214 | Randomized, double-blind study of risankizumab for genital and scalp psoriasis; confirms existing psoriasis indication, not a new-indication signal. |
| NCT04908475 | Phase 4 | Completed | 352 | Open-label study comparing risankizumab to apremilast in moderate plaque psoriasis; existing-indication comparative effectiveness data. |
| NCT04818385 | N/A | Completed | 240 | Taiwan-based prospective observational cohort on durability of risankizumab response (PASI90) vs other biologics in chronic plaque psoriasis. |
| NCT07021495 | N/A | Recruiting | 840 | Multi-center observational biomarker study profiling six immune-mediated inflammatory skin diseases including atopic dermatitis; provides mechanistic/biomarker context rather than treatment efficacy. |
| NCT07041112 | N/A | Completed | 1000 | Retrospective pharmacogenetic study on biologic drug survival in cutaneous psoriasis; indirect relevance via genetic/metabolic predictors. |
| NCT07352566 | Phase 4 | Not yet recruiting | 10 | Exploratory microdevice study testing FDA-approved atopic dermatitis/psoriasis drugs via intradermal delivery; small, early-stage, low evidentiary weight. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36588137 | 2023 | RCT | Dermatology and Therapy | Phase 2 RCT results: risankizumab tested in moderate-to-severe AD, rationale based on Th2/Th22/Th17 pathway overlap and IL-23/IL-22 blockade. |
| 39201826 | 2024 | Review | Children (Basel) | Narrative review of biologics/small molecules for pediatric alopecia areata, psoriasis, AD, and hidradenitis suppurativa. |
| 33078990 | 2020 | Review | Expert Opin Biol Ther | Review of current/emerging biologics for pediatric atopic dermatitis, including IL-23-targeted agents in trials. |
| 40856907 | 2025 | Review | Am J Clin Dermatol | Systematic review of systemic therapies (including risankizumab) for erythrodermic psoriasis management. |
| 38607726 | 2024 | Review | Military Medicine | Reappraisal of systemic immunomodulators for psoriasis and eczema, relevant to service-member populations. |
| 40794374 | 2025 | Review | Inflammopharmacology | Systematic review of IL-inhibitor therapeutic and paradoxical effects in lichen planus, an inflammatory dermatosis. |
| 31098898 | 2019 | Review | Drugs | “First Global Approval” review — confirms mechanism (anti-IL-23p19 mAb) and original psoriasis-family approval. |
| 39668419 | 2025 | Cohort | Int J Dermatol | Effectiveness/safety of combined dupilumab and risankizumab in patients with concomitant AD and psoriasis. |
| 40071317 | 2025 | Cohort | Experimental Dermatology | Retrospective study of risankizumab in patients with history of erythrodermic psoriasis; predictors of response. |
| 37381703 | 2023 | Case Report | J Dermatolog Treat | Case report of acrodermatitis continua of Hallopeau successfully and rapidly treated with risankizumab. |
US Market Information
Risankizumab has no marketing authorizations recorded in this jurisdiction (market status: Not Marketed; 0 total licenses). No license-level data (authorization number, product name, dosage form, approved indication text) is available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2 RCT directly tested risankizumab in atopic dermatitis (NCT03706040 / PMID 36588137), giving this candidate real interventional evidence (L2) rather than prediction alone. However, the predicted category “dermatitis” is broad, the mechanistic fit to AD (Th2-driven) is weaker than to psoriasis (Th17/IL-23-driven, already approved), and most of the surrounding trial/literature evidence in this pack pertains to risankizumab’s existing psoriasis indication rather than new-indication support.
To proceed, the following is needed:
- TFDA label warnings/contraindications (currently a blocking data gap — required before any S1 safety pre-assessment)
- Confirmed mechanism-of-action documentation from DrugBank (currently a data gap affecting mechanistic-linkage confidence)
- Clarification of which specific dermatitis subtype (atopic dermatitis vs. broader category) the prediction targets, since evidence strength varies substantially by subtype
- Later-phase (Phase 3) confirmatory trial data in atopic dermatitis before considering this beyond a guardrailed/exploratory status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.